Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Compound efflux in Helicobacter pylori.

Amy Kutschke1, Boudewijn L M de Jonge

  • 1Infection Discovery, Cancer and Infection Research Area, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, USA.

Antimicrobial Agents and Chemotherapy
|June 28, 2005
PubMed
Summary

Helicobacter pylori possesses an active multidrug efflux mechanism, identified as hefC. This efflux is proton motive force-dependent, contributing to the bacterium's resistance to various compounds.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epidemiology of Carbapenem Resistance Determinants Identified in Meropenem-Nonsusceptible <i>Enterobacterales</i> Collected as Part of a Global Surveillance Program, 2012 to 2017.

Antimicrobial agents and chemotherapy·2021
Same author

Antibacterial Spiropyrimidinetriones with N-Linked Azole Substituents on a Benzisoxazole Scaffold Targeting DNA Gyrase.

Journal of medicinal chemistry·2020
Same author

Longitudinal analysis of ESBL and carbapenemase carriage among Enterobacterales and Pseudomonas aeruginosa isolates collected in Europe as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance programme, 2013-17.

The Journal of antimicrobial chemotherapy·2020
Same author

<i>In Vitro</i> Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015.

Antimicrobial agents and chemotherapy·2019
Same author

<i>In Vitro</i> Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015.

Antimicrobial agents and chemotherapy·2018
Same author

In vitro activity of ceftazidime/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012-15.

The Journal of antimicrobial chemotherapy·2018

Area of Science:

  • Microbiology
  • Molecular Biology
  • Biochemistry

Background:

  • Helicobacter pylori is a significant human pathogen.
  • Understanding multidrug efflux mechanisms is crucial for combating bacterial infections.

Purpose of the Study:

  • To investigate the role of hefC in Helicobacter pylori.
  • To determine the involvement of hefC in multidrug efflux.
  • To elucidate the energy dependence of this efflux mechanism.

Main Methods:

  • Susceptibility testing using structurally unrelated compounds.
  • Ethidium bromide accumulation assays.
  • Proton motive force measurements.

Main Results:

  • The hefC gene in Helicobacter pylori was implicated in multidrug efflux.
  • Efflux activity was observed against a range of compounds.
  • Ethidium bromide accumulation confirmed the dependence on proton motive force.

Conclusions:

  • Helicobacter pylori possesses an active, proton motive force-driven multidrug efflux system.
  • The hefC gene product is a key component of this efflux mechanism.
  • This finding has implications for understanding and overcoming antimicrobial resistance in H. pylori.

Related Experiment Videos